Recipharm, a global leader in contract development and manufacturing (CDMO), has announced a strategic partnership with ProductLife Group (PLG), a prominent provider of product development and regulatory affairs services. The collaboration is set to help biopharmaceutical companies speed up their path to clinical trials and market entry, while minimizing regulatory, compliance, and supply chain complexities throughout the development lifecycle.
This partnership combines Recipharm’s robust, end-to-end capabilities in small molecule, biologics, and advanced therapy medicinal product (ATMP) development and manufacturing with PLG’s extensive global expertise in regulatory strategy, market access, and pharmacovigilance. The integrated offering will provide pharmaceutical and biotech clients with seamless support from early-stage development through to approval and commercialization-ultimately accelerating the availability of vital medicines worldwide.
Recipharm’s customers will now benefit from immediate access to PLG’s regulatory and product development expertise, enhancing alignment between clinical development, compliance, and market entry strategies. By embedding PLG into its service offering, Recipharm enables clients to “begin with the end in mind,” ensuring early and proactive integration of regulatory and commercial planning alongside scale-up and production.
Also Read: Illumina and Ovation.io Launch Groundbreaking GLP-1 Multiomic Dataset to Accelerate Therapeutic Development
Conversely, PLG’s clients gain access to Recipharm’s global manufacturing infrastructure and advanced development capabilities, including smart, integrated services and predictive biologics production models. This holistic approach supports faster, more cost-effective development, offering tailored solutions that meet the evolving needs of a global market.
“This partnership brings together Recipharm’s development and manufacturing expertise, with PLG’s 2,000 regulatory experts, operating across 150 countries. By integrating scientific, regulatory, operational and commercial strategy from the outset we help our customers move faster, avoid costly delays and build confidence that their product submissions will meet and exceed, agency requirements, for critical medicines worldwide,” said Greg Behar, CEO of Recipharm.
“As regulatory complexity grows, our clients need integrated solutions that connect strategy and execution. With Recipharm’s 700 product development experts and over 400 projects delivered annually, this partnership allows us to embed regulatory thinking directly into product development and operational planning. Together, we help our clients ensure compliance and build stronger submissions from the start,” added Xavier Duburcq, CEO of PLG.